Mutual Advisors LLC Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Mutual Advisors LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,689 shares of the medical research company’s stock after buying an additional 218 shares during the quarter. Mutual Advisors LLC’s holdings in IQVIA were worth $334,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Simplify Asset Management Inc. increased its stake in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the period. Nordea Investment Management AB increased its stake in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. Versor Investments LP acquired a new stake in shares of IQVIA in the third quarter valued at $1,328,000. JPMorgan Chase & Co. grew its stake in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its holdings in IQVIA by 17.9% during the 4th quarter. Crossmark Global Holdings Inc. now owns 14,362 shares of the medical research company’s stock worth $2,822,000 after purchasing an additional 2,182 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Truist Financial lowered their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Morgan Stanley cut their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, The Goldman Sachs Group lowered their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Stock Down 1.6 %

IQV stock opened at $203.59 on Wednesday. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market cap of $36.95 billion, a price-to-earnings ratio of 26.72, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The company has a fifty day moving average price of $200.02 and a 200 day moving average price of $221.09.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.